Pheon Therapeutics, a leading Antibody-Drug Conjugate (ADC) specialist based in Harpenden, UK, developing next generation ADCs for a wide range of hard-to-treat cancers, launched today following the closing of a $68 million Series A financing in March 2022. The investment will enable Pheon to advance its lead ADC program to clinical proof-of-concept and establish a pipeline of novel ADCs. Source: Pheon press release 28/9/2022